Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2692
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBakan, Feray-
dc.contributor.authorCakmak, Melike Cokol-
dc.contributor.authorCokol, Murat-
dc.contributor.authorDenkbas, Emir Baki-
dc.contributor.authorKara, Goknur-
dc.contributor.authorParlar, Ayhan-
dc.date.accessioned2022-08-17T07:07:45Z-
dc.date.available2022-08-17T07:07:45Z-
dc.date.issued2020-
dc.identifier.urihttp://doi.org/10.1016/j.colsurfb.2020.111340-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2692-
dc.description.abstractWith the development of nanotechnology, various drug delivery systems including inorganic nanoparticles, liposomes, polymers, etc. have been developed over the past decade. Some of these nanoparticles are also forthcoming candidates for the successful delivery of small interfering RNA (siRNA) for targeted gene silencing. Upon its discovery, siRNA was perceived as a highly promising agent in the treatment of various diseases. However, it could not exhibit the expected clinical outcomes owing to the unfavorable challenges during delivery. One such challenge was identified as the lack of an effective carrier. Among the carriers, calcium phosphate (CaP) nanoparticles have attracted remarkable attention due to the superior biochemical properties and hold great promise for siRNA. It is well known that synthesis conditions influence the types of crystalline phases of CaPs as well as morphology. In this study, to address the influence of these parameters on the success of siRNA delivery, three different arginine (Arg) modified CaP nanoparticles having different chemical and morphological characteristics were synthesized as being the carriers of two specific siRNAs against survivin and cyclin B1. The functioning of CaP surfaces with Arg results in positive zeta potential on the surfaces. Functionalized nanoparticles have a higher loading capacity compared to unmodified particles, as they have a cationic surface that can be easily attached to negatively charged siRNAs. The gene silencing ability and the consequent in vitro antitumor activity of these CaP-Arg-siRNA complexes were investigated using A549 non-small-cell lung cancer cells. We found that high survivin and cyclin B1 expression is associated with worse survival in patients with lung cancer based on the Kaplan-Meier database. Considering the promoting role of survivin and cyclin B1 in cancer development and progression, CaP-Arg-siRNA mediated suppression of these genes resulted in a significant decrease in cell growth and induction of apoptosis. Our data suggest that all three CaP-Arg nanoparticles synthesized in this work can be used as safe and efficient nanocarriers for siRNA delivery, offering the opportunity to develop new therapeutic strategies for the treatment of lung cancer.en_US
dc.language.isoengen_US
dc.publisherELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDSen_US
dc.relation.isversionof10.1016/j.colsurfb.2020.111340en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectsiRNA delivery; Gene silencing; Calcium phosphate; Nanoparticles; Non-small-cell lung cancer; In vitro deliveryen_US
dc.titleSilencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapyen_US
dc.typearticleen_US
dc.relation.journalCOLLOIDS AND SURFACES B-BIOINTERFACESen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.contributor.authorID0000-0002-5905-9758en_US
dc.identifier.volume196en_US
Appears in Collections:Kimya

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.